Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967501 | 1.00 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTCTDSP1KDM4E | |
| SCHEMBL3408982 | 0.92 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTCTDSP1KDM4E | |
| SCHEMBL740361 | 0.81 | ADORA3 (0.49) | ALDH1A1LMNAMAPTCTDSP1KDM4E | |
| SCHEMBL740362 | 0.81 | ADORA3 (0.49) | ALDH1A1LMNAMAPTCTDSP1KDM4E | |
| SCHEMBL14523934 | 0.79 | ERBB2 (0.50) | MAPTSMN1; SMN2ERBB2CYP2C19 | |
| SCHEMBL5758992 | 0.79 | CYP4F2 (0.42) | ALDH1A1MAPTCTDSP1KDM4EPOLB | |
| SCHEMBL5763599 | 0.79 | FFAR1 (0.53) | ERBB2 | |
| SCHEMBL5758996 | 0.79 | CYP4F2 (0.42) | ALDH1A1MAPTCTDSP1KDM4EPOLB | |
| SCHEMBL5763596 | 0.79 | FFAR1 (0.53) | ERBB2 | |
| SCHEMBL5761110 | 0.79 | CYP4F2 (0.43) | ALDH1A1MAPTCTDSP1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | ALDH1A1 279/4885LMNA 3709/4885MAPT 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.